Wilson Sonsini Goodrich & Rosati represented IVIVA in the transaction. United Therapeutics (Nasdaq:UTHR) announced it acquisition of all of the outstanding equity of IVIVA Medical, Inc., a...
United Therapeutics’ Acquisition of IVIVA
ATP’s Launch of Ascidian Therapeutics
Wilson Sonsini Goodrich & Rosati advised Ascidian Therapeutics on the deal. Life sciences venture capital firm ATP announced the launch of new biotechnology company Ascidian Therapeutics....
NAPIGEN’s $7.85 Million Seed Financing
Wilson Sonsini advised NAPIGEN on the deal. NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, announced the completion of $7.85 million seed...